PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. NTHI
9. SPY
10. EVMN

Go back to PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
(NASDAQ: PEPG) Delayed: 3.27 +0.06 (1.87%)
Previous Close $3.21    52 Week High $ 
Open $3.17    52 Week Low $ 
Day High $3.48    P/E N/A 
Day Low $3.17    EPS $ 
Volume 542,019